Zhuo Chuanjun, Ji Feng, Xiao Bo, Lin Xiaodong, Chen Ce, Jiang Deguo, Ma Xiaoyan, Li Ranli, Liu Sha, Xu Yong, Wang Wenqiang
School of Mental Health, Jining Medical University, Jining, Shandong 272119, China; Psychiatric-Neuroimaging-Genetics Laboratory, Wenzhou Seventh People's Hospital, Wenzhou, Zhejiang 325000, China; Psychiatric-Neuroimaging-Genetics-Comorbidity Laboratory, Tianjin Mental Health Centre, Mental Health Teaching Hospital of Tianjin Medical University, Tianjin Anding Hospital, Tianjin 300222, China; Department of Psychiatry, First Hospital/First Clinical Medical College of Shanxi Medical University, Taiyuan, China; MDT Center for Cognitive Impairment and Sleep Disorders, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China; Co-collaboration Laboratory of China and Canada, Xiamen Xianyue Hospital and University of Alberta, Xiamen, Fujian 361000, China.
School of Mental Health, Jining Medical University, Jining, Shandong 272119, China.
Psychiatry Res. 2020 Mar 1;286:112906. doi: 10.1016/j.psychres.2020.112906.
Define changes in the visual cortex and retina in first-episode schizophrenia patients with visual disturbance (FUSCHVD) accompanied by antipsychotic agent treatment is important for guiding treatment. We examined the visual system prior to and after 3 years of antipsychotic-agent treatment in 48 patients with FUSCHVD and 50 healthy controls, and after 3.5 years of antipsychotic-agent treatment in 12 patients with FUSCHVD and 12 healthy subjects who came from the cohort with 3 years of follow up. Reduction of the visual cortex gray matter volume (GMV) was observed in patients compared to healthy controls, and impairments deteriorated accompanied with 3 years' treatment with antipsychotic agents. Total retinal thickness was also reduced in patients but did not deteriorated with treatment with antipsychotic agents. However, in the 12 patients who performed the additional 6-month follow-up, GMV and total retinal thickness reductions did not demonstrate any further trend in deterioration. These findings indicate that the reductions of GMV and retinal thickness may be self-limited. Although these findings were consistent with previous reports, it was only observed in a small number of patients. Therefore, clinicians should remain pay greater attention to visual system impairment in FUSCHVD.
明确伴有抗精神病药物治疗的首发精神分裂症伴视觉障碍患者（FUSCHVD）视觉皮层和视网膜的变化对于指导治疗很重要。我们在48例FUSCHVD患者和50例健康对照者接受抗精神病药物治疗3年之前和之后，以及在来自3年随访队列的12例FUSCHVD患者和12例健康受试者接受抗精神病药物治疗3.5年之后，对视觉系统进行了检查。与健康对照者相比，患者的视觉皮层灰质体积（GMV）减少，并且在接受3年抗精神病药物治疗后损伤恶化。患者的视网膜总厚度也降低，但未因抗精神病药物治疗而恶化。然而，在进行额外6个月随访的12例患者中，GMV和视网膜总厚度的降低未显示出任何进一步恶化的趋势。这些发现表明GMV和视网膜厚度的降低可能是自限性的。尽管这些发现与先前的报告一致，但仅在少数患者中观察到。因此，临床医生应更加关注FUSCHVD患者的视觉系统损伤。
